Tag: NatcoPharma
-
Natco Pharma Secures USFDA Approval for Bosentan Tablets for Oral Suspension (32mg): A Game-Changer in PAH Treatment
Natco Pharma has received USFDA approval for its generic Bosentan tablets for oral suspension (32mg), a key treatment for pediatric pulmonary arterial hypertension (PAH). With First-to-File status, Natco is poised to capture significant market share through a 180-day exclusivity period. This approval opens new opportunities for Natco and its partner Lupin Pharmaceuticals in the growing U.S. pediatric PAH market, addressing a critical need for easier-to-administer treatments.
-
Natco Pharma Secures Approval for Generic Everolimus Tablets for Oral Suspension in the U.S.
Natco Pharma has received FDA approval for its generic version of Everolimus tablets for oral suspension (TFOS), providing a more affordable treatment option for patients with TSC-related SEGA. This approval marks a significant milestone in the generics market, offering greater access to a critical therapy for both adult and pediatric patients.